Akari Therapeutics (NASDAQ:AKTX) was upgraded by stock analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a report issued on Thursday.
Other equities analysts have also recently issued research reports about the company. Zacks Investment Research cut Akari Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 26th. Chardan Capital restated a “neutral” rating on shares of Akari Therapeutics in a report on Sunday, September 17th. William Blair upgraded Akari Therapeutics from a “market perform” rating to an “outperform” rating in a report on Friday, September 22nd. Finally, Canaccord Genuity restated a “buy” rating and set a $15.00 price objective on shares of Akari Therapeutics in a report on Friday, September 22nd. One analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $7.50.
Shares of Akari Therapeutics (NASDAQ AKTX) traded down $0.12 during trading on Thursday, hitting $4.86. The stock had a trading volume of 108,511 shares, compared to its average volume of 370,956. Akari Therapeutics has a 12-month low of $3.18 and a 12-month high of $22.20.
WARNING: “Akari Therapeutics (AKTX) Upgraded by ValuEngine to Sell” was posted by American Banking News and is owned by of American Banking News. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this story can be accessed at https://www.americanbankingnews.com/2017/11/30/akari-therapeutics-aktx-upgraded-by-valuengine-to-sell.html.
About Akari Therapeutics
Akari Therapeutics, Plc, formerly Celsus Therapeutics Plc, is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5), including paroxysmal nocturnal hemoglobinuria, Guillain Barre syndrome and atypical Hemolytic Uremic Syndrome.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Akari Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics PLC and related companies with MarketBeat.com's FREE daily email newsletter.